http://orcid.org/0000-0002-2226-0239
Citations (61)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Zhou Liu, Xiubing Hang, Tao Yan, Wenwen Chu, Zhen Gong, Yanyan Liu, Yuanyuan Dai, Min Yang, Jiabin Li & Qiang Zhou. (2023) A Simple Disk Stacking Plus Micro-Elution Method for Rapid Detection of the Synergistic Effect of Aztreonam and Ceftazidime/Avibactam Against Metallo-β-Lactamase Producing Enterobacterales. Infection and Drug Resistance 16, pages 1537-1543.
Read now
Read now
Daniele Roberto Giacobbe, Jason A. Roberts, Mohd H. Abdul-Aziz, Etienne de Montmollin, Jean-François Timsit & Matteo Bassetti. (2022) Treatment of ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacteria with novel agents: a contemporary, multidisciplinary ESGCIP perspective. Expert Review of Anti-infective Therapy 20:7, pages 963-979.
Read now
Read now
FA Varón-Vega, E Lemos, Gamboa N Castaño & JM Reyes. (2022) Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant Klebsiella pneumoniae in Colombia. Expert Review of Pharmacoeconomics & Outcomes Research 22:2, pages 235-240.
Read now
Read now
Ilias Karaiskos, Irene Galani, Vassiliki Papoutsaki, Lamprini Galani & Helen Giamarellou. (2022) Carbapenemase producing Klebsiella pneumoniae: implication on future therapeutic strategies. Expert Review of Anti-infective Therapy 20:1, pages 53-69.
Read now
Read now
Júlia Sellarès-Nadal, Simeón Eremiev, Joaquin Burgos & Benito Almirante. (2021) An overview of cilastatin + imipenem + relebactam as a therapeutic option for hospital-acquired and ventilator-associated bacterial pneumonia: evidence to date. Expert Opinion on Pharmacotherapy 22:12, pages 1521-1531.
Read now
Read now
Xiangyi Cui, Yuhong Lü & Changwu Yue. (2021) Development and Research Progress of Anti-Drug Resistant Bacteria Drugs. Infection and Drug Resistance 14, pages 5575-5593.
Read now
Read now
Chiara Adembri, Iacopo Cappellini & Andrea Novelli. (2020) The role of PK/PD–based strategies to preserve new molecules against multi-drug resistant gram-negative strains. Journal of Chemotherapy 32:5, pages 219-225.
Read now
Read now
Rajeev Soman, Balaji Veeraraghavan, Ashit Hegde, Prakash Jiandani, Yatin Mehta, Vasant Nagavekar, Camilla Rodrigues, R K Singh, Subramanian Swaminathan, Subhash Todi, Subhash Varma, Saiprasad Patil & Hanmant Barkate. (2019) Indian consensus on the management of CRE infection in critically ill patients (ICONIC) — India. Expert Review of Anti-infective Therapy 17:8, pages 647-660.
Read now
Read now
Michaela Simon, Josef Koestler, Udo Reischl, André Gessner & Jonathan Jantsch. (2019) Detection of carbapenemase-producing Enterobacterales and the BD Phoenix CPO Detect panel. Expert Review of Molecular Diagnostics 19:8, pages 659-665.
Read now
Read now
Articles from other publishers (52)
Gabriela da Silva Collar, Natália Kehl Moreira, Priscila Lamb Wink, Afonso Luís Barth, Otávio Hallal Ferreira Raro, Cícero Dias, Adriano de Lima Machado, Mariana Preussler Mott & Juliana Caierão. (2023) Detection of polymyxins resistance among Enterobacterales: evaluation of available methods and proposal of a new rapid and feasible methodology. Annals of Clinical Microbiology and Antimicrobials 22:1.
Crossref
Crossref
Ilias Karaiskos, Aikaterini Gkoufa, Elena Polyzou, Georgios Schinas, Zoe Athanassa & Karolina Akinosoglou. (2023) High-Dose Nebulized Colistin Methanesulfonate and the Role in Hospital-Acquired Pneumonia Caused by Gram-Negative Bacteria with Difficult-to-Treat Resistance: A Review. Microorganisms 11:6, pages 1459.
Crossref
Crossref
Yamuna Devi Bakthavatchalam, Divyaa Elangovan, Subha Vajjiravelu Jaganathan, Nivedhana Subburaju, Abirami Shankar, Yuvasri Manokaran, Sudarsana J., Rema Devi, Sujata Baveja, Sheela Devi, Jayakumar S., Sanjay Bhattacharya, Rudresh S. M., Bineshlal Yesudhason, Vignesh Shetty, Ankur Mutreja, Abi Manesh, George M. Varghese, Charis A. Marwick, Benjamin J. Parcell, Ian H. Gilbert & Balaji Veeraraghavan. (2023)
In Vitro
Activity of Two Cefepime-Based Novel Combinations, Cefepime/Taniborbactam and Cefepime/Zidebactam, against Carbapenemase-Expressing
Enterobacterales
Collected in India
. Microbiology Spectrum 11:2.
Crossref
Crossref
Salvatore Lucio Cutuli, Veronica Gennenzi, Joel Vargas & Gennaro De Pascale. 2023. Endotoxin Induced-Shock: a Multidisciplinary Approach in Critical Care. Endotoxin Induced-Shock: a Multidisciplinary Approach in Critical Care
49
55
.
Matteo Bassetti, Federica Magnè, Daniele Roberto Giacobbe, Lorenzo Bini & Antonio Vena. (2022) New antibiotics for Gram-negative pneumonia. European Respiratory Review 31:166, pages 220119.
Crossref
Crossref
Dana Bakdach, Reem Elajez, Abdul Rahman Bakdach, Ahmed Awaisu, Gennaro De Pascale & Ali Ait Hssain. (2022) Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation. Journal of Clinical Medicine 11:23, pages 6898.
Crossref
Crossref
Maxime Danjean, Claire Amaris Hobson, Maud Gits-Muselli, Céline Courroux, Audrey Monjault, Stéphane Bonacorsi & André Birgy. (2022) Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales. Clinical Microbiology and Infection 28:11, pages 1503.e1-1503.e3.
Crossref
Crossref
Hajar Alqahtani, Ahlam Alghamdi, Nouf Alobaidallah, Amal Alfayez, Rawan Almousa, Rawan Albagli, Nour Shamas, Fayssal Farahat, Ebrahim Mahmoud, Mohammad Bosaeed & Reem Abanamy. (2022) Evaluation of ceftazidime/avibactam for treatment of carbapenemase-producing carbapenem-resistant Enterobacterales with OXA-48 and/or NDM genes with or without combination therapy. JAC-Antimicrobial Resistance 4:5.
Crossref
Crossref
Olga Riabova, Anna Egorova, Alexander Lepioshkin, Yan Li, Kerstin Voigt, Florian Kloss & Vadim Makarov. (2022)
Thieno[2,3‐
d
]pyrimidine‐Core Compounds Show Activity against Clinically Relevant Gram‐Positive Bacteria
. ChemMedChem 17:17.
Crossref
Crossref
Xinrui Zhao, Yongxin Jin, Fang Bai, Zhihui Cheng, Weihui Wu & Xiaolei Pan. (2022)
Mutation of
PA4292
in Pseudomonas aeruginosa Increases β-Lactam Resistance through Upregulating Pyocyanin Production
. Antimicrobial Agents and Chemotherapy 66:7.
Crossref
Crossref
Matteo Bassetti, Alessandra Mularoni, Daniele Roberto Giacobbe, Nadia Castaldo & Antonio Vena. (2022) New Antibiotics for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia. Seminars in Respiratory and Critical Care Medicine 43:02, pages 280-294.
Crossref
Crossref
Tingting Xu, Yuqi Guo, Yang Ji, Baohong Wang & Kai Zhou. (2022) Epidemiology and Mechanisms of Ceftazidime–Avibactam Resistance in Gram-Negative Bacteria. Engineering 11, pages 138-145.
Crossref
Crossref
Mustafa GÜZEL, Duygu ÖCAL, İlke TOKER ÖNDER, Doğan AKDOĞAN, Gül BAHAR ERDEM & Orhan AKPINAR. (2022) Comparison of in Vitro Antimicrobial Efficacy of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Combination Against Carbapenem-Resistant Enterobacteriaceae Species Isolated from Various Clinical SpecimensÇeşitli Klinik Örneklerden İzole Edilen Karbapenem Dirençli Enterobacteriaceae İzolatlarına Karşı Seftolozan-Tazobaktam ve Seftazidim-Avibaktam Kombinasyonlarının In Vitro Antimikrobiyal Etkinliğinin Karşılaştırılması. Konuralp Tıp Dergisi 14:1, pages 75-80.
Crossref
Crossref
Casin Le, Camila Pimentel, Fernando Pasteran, Marisel R. Tuttobene, Tomás Subils, Jenny Escalante, Brent Nishimura, Susana Arriaga, Aimee Carranza, Vyanka Mezcord, Alejandro J. Vila, Alejandra Corso, Luis A. Actis, Marcelo E. Tolmasky, Robert A. Bonomo & Maria Soledad Ramírez. (2022) Human Serum Proteins and Susceptibility of Acinetobacter baumannii to Cefiderocol: Role of Iron Transport. Biomedicines 10:3, pages 600.
Crossref
Crossref
Tsung-Ying Yang, Ya-Ju Hsieh, Li-Ting Kao, Guan Hong Liu, Shao-Hsuan Lian, Liang-Chun Wang, I-Ling Lin, Hsian-Yu Wang, Sung-Pin Tseng & Po-Liang Lu. (2022) Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan. Journal of Microbiology, Immunology and Infection 55:1, pages 86-94.
Crossref
Crossref
Nenad Macesic, Luke V. Blakeway, James D. Stewart, Jane Hawkey, Kelly L. Wyres, Louise M. Judd, Ryan R. Wick, Adam W. Jenney, Kathryn E. Holt & Anton Y. Peleg. (2021) Silent spread of mobile colistin resistance gene mcr-9.1 on IncHI2 ‘superplasmids’ in clinical carbapenem-resistant Enterobacterales. Clinical Microbiology and Infection 27:12, pages 1856.e7-1856.e13.
Crossref
Crossref
Matteo Bassetti & Javier Garau. (2021) Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections. Journal of Antimicrobial Chemotherapy 76:Supplement_4, pages iv23-iv37.
Crossref
Crossref
Federica Romanelli, Stefania Stolfa, Anna Morea, Luigi Ronga, Raffaele Del Prete, Maria Chironna, Luigi Santacroce & Adriana Mosca. (2021)
Meropenem/vaborbactam activity
in vitro
: a new option for
Klebsiella pneumoniae
carbapenemase (KPC)-producing
Klebsiella pneumoniae
treatment
. Future Microbiology 16:16, pages 1261-1266.
Crossref
Crossref
Márió Gajdács, Zoltán Bátori & Katalin Burián. (2021) Interplay between Phenotypic Resistance to Relevant Antibiotics in Gram-Negative Urinary Pathogens: A Data-Driven Analysis of 10 Years’ Worth of Antibiogram Data. Life 11:10, pages 1059.
Crossref
Crossref
Yu-Lin Lee, Wen-Chien Ko, Wen-Sen Lee, Po-Liang Lu, Yen-Hsu Chen, Shu-Hsing Cheng, Min-Chi Lu, Chi-Ying Lin, Ting-Shu Wu, Muh-Yong Yen, Lih-Shinn Wang, Chang-Pan Liu, Pei-Lan Shao, Zhi-Yuan Shi, Yao-Shen Chen, Fu-Der Wang, Shu-Hui Tseng, Chao-Nan Lin, Yu-Hui Chen, Wang-Huei Sheng, Chun-Ming Lee, Hung-Jen Tang & Po-Ren Hsueh. (2021) In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017–2020. International Journal of Antimicrobial Agents 58:3, pages 106377.
Crossref
Crossref
Abdul S Ansari. (2021) Therapeutic Options for the Treatment of Carbapenem-resistant Enterobacteriaceae Infections: Hope in the Times of Hype and Despair. Indian Journal of Critical Care Medicine 25:7, pages 752-753.
Crossref
Crossref
Anand Shah, Vasant Nagvekar, Vrajeshkumar P Unadkat, Amol Chavan, Ruhi Kohli, Shailendra Hodgar, Aashita Ashpalia, Niranjan Patil & Rahul Kamble. (2021) Clinical Outcome of Patients on Ceftazidime–Avibactam and Combination Therapy in Carbapenem-resistant Enterobacteriaceae. Indian Journal of Critical Care Medicine 25:7, pages 780-784.
Crossref
Crossref
Erin N. Deja. (2021) Novel ß-Lactamase Inhibitors: New Weapons in the Arms Race against Antimicrobial Resistance. Clinical Microbiology Newsletter 43:14, pages 119-125.
Crossref
Crossref
Abigail M. Rubio, Ellen G. Kline, Chelsea E. Jones, Liang Chen, Barry N. Kreiswirth, M. Hong Nguyen, Cornelius J. Clancy, Vaughn S. Cooper, Ghady Haidar, Daria Van Tyne & Ryan K. Shields. (2021)
In Vitro
Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam
. Antimicrobial Agents and Chemotherapy 65:6.
Crossref
Crossref
Fernando Pasteran, Jose Cedano, Michelle Baez, Ezequiel Albornoz, Melina Rapoport, Jose Osteria, Sabrina Montaña, Casin Le, Grace Ra, Robert A. Bonomo, Marcelo E. Tolmasky, Mark Adams, Alejandra Corso & Maria Soledad Ramirez. (2021) A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant Acinetobacter baumannii (CRAB) Isolates. Antibiotics 10:5, pages 577.
Crossref
Crossref
Corneliu Ovidiu Vrancianu, Elena Georgiana Dobre, Irina Gheorghe, Ilda Barbu, Roxana Elena Cristian & Mariana Carmen Chifiriuc. (2021) Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing Enterobacterales Infections. Microorganisms 9:4, pages 730.
Crossref
Crossref
Rajeev Soman, Yamuna Devi Bakthavatchalam, Abinaya Nadarajan, Hariharan Triplicane Dwarakanathan, Ramasubramanian Venkatasubramanian & Balaji Veeraraghavan. (2020) Is it time to move away from polymyxins?: evidence and alternatives. European Journal of Clinical Microbiology & Infectious Diseases 40:3, pages 461-475.
Crossref
Crossref
I Karaiskos, G L Daikos, A Gkoufa, G Adamis, A Stefos, S Symbardi, G Chrysos, E Filiou, D Basoulis, E Mouloudi, L Galani, K Akinosoglou, K Arvaniti, A Masgala, M Petraki, E Papadimitriou, I Galani, G Poulakou, C Routsi, H Giamarellou, V Papoutsaki, H Papadogeorgaki, C Tsapas, M Astriti, V Romanou, E Makronassios, P Giona, K Pontikis, N Gatselis, E Massa, E Michailidou & C Gogos. (2021)
Ceftazidime/avibactam in the era of carbapenemase-producing
Klebsiella pneumoniae
: experience from a national registry study
. Journal of Antimicrobial Chemotherapy 76:3, pages 775-783.
Crossref
Crossref
Rémy A. Bonnin, Agnès B. Jousset, Cécile Emeraud, Saoussen Oueslati, Laurent Dortet & Thierry Naas. (2021) Genetic Diversity, Biochemical Properties, and Detection Methods of Minor Carbapenemases in Enterobacterales. Frontiers in Medicine 7.
Crossref
Crossref
Mikhail V. Edelstein, Elena Yu. Skleenova, Ivan V. Trushin, Alexey Yu. Kuzmenkov, Alexey А. MartinovichEvgenij A. Shek, Elvira R. Shajdullina, Andrey A. Avramenko, Alina G. Vinogradova, Nataly V. Ivanchik, Marina V. Sukhorukova, Andrey V. Romanov, Anna V. Mikotina, Ilya S. Azyzov, Andrey V. Dekhnich & Roman S. Kozlov. (2021) Susceptibility of clinical Enterobacterales and Pseudomonas aeruginosa isolates to ceftazidimeavibactam in Russia: multicenter local laboratory databased surveillance. Clinical Microbiology and Antimicrobial Chemotherapy 23:3, pages 264-278.
Crossref
Crossref
Ronan R. McCarthy, Gerald J. Larrouy-Maumus, Mei Gei C. Meiqi Tan & David W. Wareham. 2021. Microbial Pathogenesis. Microbial Pathogenesis
135
153
.
Dafna Yahav, Christian G. Giske, Alise Grāmatniece, Henrietta Abodakpi, Vincent H. Tam & Leonard Leibovici. (2020) New β-Lactam–β-Lactamase Inhibitor Combinations. Clinical Microbiology Reviews 34:1.
Crossref
Crossref
Enea Gino Di Domenico, Ilaria Cavallo, Francesca Sivori, Francesco Marchesi, Grazia Prignano, Fulvia Pimpinelli, Isabella Sperduti, Lorella Pelagalli, Fabiola Di Salvo, Ilaria Celesti, Silvia Paluzzi, Carmelina Pronesti, Tatiana Koudriavtseva, Fiorentina Ascenzioni, Luigi Toma, Assunta De Luca, Andrea Mengarelli & Fabrizio Ensoli. (2020) Biofilm Production by Carbapenem-Resistant Klebsiella pneumoniae Significantly Increases the Risk of Death in Oncological Patients. Frontiers in Cellular and Infection Microbiology 10.
Crossref
Crossref
Stamatis Karakonstantis, Evangelos I Kritsotakis & Achilleas Gikas. (2020) Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems. Infection 48:6, pages 835-851.
Crossref
Crossref
Dillon A. Hayden, Bryan P. White & Kiya K. Bennett. (2020)
Review of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem/Cilastatin-Relebactam to Target
Klebsiella pneumoniae
Carbapenemase-Producing Enterobacterales
. Journal of Pharmacy Technology 36:5, pages 202-210.
Crossref
Crossref
Elza Ferreira Firmo, Jorge Belém Oliveira Júnior, Alexsandra Maria Lima Scavuzzi, Luis Carlos Alves, Fábio André Brayner, Dyana Leal Veras & Ana Catarina de Souza Lopes. (2020) In vitro activity of polymyxin B in combination with meropenem, amikacin and gentamicin against Klebsiella pneumoniae clinical isolates co-harbouring aminoglycoside-modifying enzymes, blaNDM-1 and blaKPC-2. Journal of Global Antimicrobial Resistance 22, pages 511-514.
Crossref
Crossref
Matthew W. McCarthy. (2020) Clinical Pharmacokinetics and Pharmacodynamics of Imipenem–Cilastatin/Relebactam Combination Therapy. Clinical Pharmacokinetics 59:5, pages 567-573.
Crossref
Crossref
Diana Rodríguez, María Maneiro, Juan C. Vázquez-Ucha, Alejandro Beceiro & Concepción González-Bello. (2020) 6-Arylmethylidene Penicillin-Based Sulfone Inhibitors for Repurposing Antibiotic Efficiency in Priority Pathogens. Journal of Medicinal Chemistry 63:7, pages 3737-3755.
Crossref
Crossref
Ilias Karaiskos & Helen Giamarellou. (2020) Carbapenem-Sparing Strategies for ESBL Producers: When and How. Antibiotics 9:2, pages 61.
Crossref
Crossref
Irene Galani, Ilias Karaiskos, Maria Souli, Vassiliki Papoutsaki, Lamprini Galani, Aikaterini Gkoufa, Anastasia Antoniadou & Helen Giamarellou. (2020) Outbreak of KPC-2-producing Klebsiella pneumoniae endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019. Eurosurveillance 25:3.
Crossref
Crossref
Sai Saran, NamrataS Rao & Afzal Azim. (2020) New and promising anti-bacterials: Can this promise be sustained?. Journal of Anaesthesiology Clinical Pharmacology 36:1, pages 13.
Crossref
Crossref
Zhi–Wen Li, Xi Lu, Yan–Xiang Wang, Xin–Xin Hu, Hai–Gen Fu, Li–Mei Gao, Xue–Fu You, Sheng Tang & Dan–Qing Song. (2020) Synthesis and antibacterial evaluation against resistant Gram-negative bacteria of monobactams bearing various substituents on oxime residue. Bioorganic Chemistry 94, pages 103487.
Crossref
Crossref
Basem M. Alraddadi, Mohammed Saeedi, Mohammed Qutub, Abeer Alshukairi, Ashraf Hassanien & Ghassan Wali. (2019) Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae. BMC Infectious Diseases 19:1.
Crossref
Crossref
Haoyue Che, Rui Wang, Jin Wang & Yun Cai. (2019) Ceftazidime/avibactam versus carbapenems for the treatment of infections caused by Enterobacteriaceae: A meta-analysis of randomised controlled trials. International Journal of Antimicrobial Agents 54:6, pages 809-813.
Crossref
Crossref
Xiangqing Song, Yi Wu, Lizhi Cao, Dunwu Yao & Minghui Long. (2019) Is Meropenem as a Monotherapy Truly Incompetent for Meropenem-Nonsusceptible Bacterial Strains? A Pharmacokinetic/Pharmacodynamic Modeling With Monte Carlo Simulation. Frontiers in Microbiology 10.
Crossref
Crossref
Christoph Mayer. (2019) Peptidoglycan Recycling, a Promising Target for Antibiotic Adjuvants in Antipseudomonal Therapy. The Journal of Infectious Diseases 220:11, pages 1713-1715.
Crossref
Crossref
Chih-Cheng Lai, Chi-Chung Chen & Hung-Jen Tang. (2019) Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections. Journal of Clinical Medicine 8:10, pages 1650.
Crossref
Crossref
Suay-García & Pérez-Gracia. (2019) Present and Future of Carbapenem-resistant Enterobacteriaceae (CRE) Infections. Antibiotics 8:3, pages 122.
Crossref
Crossref
Ilias Karaiskos, Styliani Lagou, Konstantinos Pontikis, Vasiliki Rapti & Garyphallia Poulakou. (2019) The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How. Frontiers in Public Health 7.
Crossref
Crossref
Márió Gajdács. (2019) The Concept of an Ideal Antibiotic: Implications for Drug Design. Molecules 24:5, pages 892.
Crossref
Crossref
Agila Kumari Pragasam, Balaji Veeraraghavan, Baby Abirami Shankar, Yamuna Devi Bakthavatchalam, Alice Mathuram, Biju George, Binila Chacko, Pritish Korula & Shalini Anandan. (2019) Will Ceftazidime/Avibactam Plus Aztreonam be Effective for NDM and OXA-48-Like Producing Organisms: Lessons Learnt from In vitro Study. Indian Journal of Medical Microbiology 37:1, pages 34-41.
Crossref
Crossref
Sheila Hernandez, Ana Paula Velez, Jorge Lamarche & John N. Greene. 2019. Infections in Neutropenic Cancer Patients. Infections in Neutropenic Cancer Patients
73
88
.